We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App




New Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia

By LabMedica International staff writers
Posted on 21 Sep 2021
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. More...
pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.

One of the most challenging issues in the management of patients with atypical pneumoniae is the rapid identification of the microbial etiology to guide and personalize the initial antimicrobial therapy. A critical factor in the selection of a diagnostic assay for respiratory infections is the time required to obtain the test result. Only those diagnostic tests that provide results within the first 24 hours can actually assist the clinician to guide the initial antimicrobial therapy.

DNA amplification using the polymerase chain reaction (PCR) is a technique with the potential to offer rapid results in the diagnosis of bacterial pneumonia. Multiplex Real-time PCR is highly sensitive technique for the rapid detection of RNA/DNA in clinical specimens. This technique is particularly advantageous for the detection of fastidious or difficult to culture organisms such as these three atypical pathogens. Several conventional PCR assays and multiplex assays have been developed and have demonstrated sensitivity and specificity better than microbiologic tests. However, a small number of these contain the needed CE-IVD marking necessary for use in clinical diagnosis.

CerTest’s CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR detection kit has been developed and validated for the detection of the principal pathogens implicated in atypical pneumoniae. The clinical validation demonstrated that the molecular assay is a sensitive, useful, cheap, and above all a rapid diagnostic tool for the management of atypical pneumonia patients. Moreover, the type of respiratory sample is not a limiting factor as the molecular assay accurately detects the pathogens in upper and lower respiratory samples. Additionally, the multiplex strategy offers an obvious and important clinical advantage as it minimizes the risk that the causative search is biased by overlapping clinical presentations of distinct causes. The application of the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR detection kit from CerTest is expected to significantly improve diagnostics for atypical pneumonia-associated bacterial pathogens.

 

Related Links:

CerTest Biotec



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.